Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Q4 2023 Omeros Corp Earnings Call
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript April 1, 2024 Omeros Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to today’s conference call from Omeros Corporation. At this time, all participants are in a […]
Reduced Net Loss and Strategic Developments Mark Omeros Corp's Year-End Financials
SEATTLE, April 01, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, wh
SEATTLE, March 27, 2024--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside potential. By mid-decade, these healthcare, industrial, and energy companies may realize their latent potential and reshape market dynamics. These industries may derive significant change as the world economy changes due to technological breakthroughs, well-timed acquisitions, and ground-breaking inven
SEATTLE, February 20, 2024--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let’s forget inflated giants and overhyped darlings. Today, the article reveals three hidden gems. The three sleeper stocks under $15 I’ll be pointing out today are audacious innovators and may erupt like financial volcanoes by 2029. The first one, a fintech, is shaking up the industry with its revolutionary app, offering everything from student loan refinancing to investing. It capitalizes on con
SEATTLE, February 01, 2024--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP ("DRI"), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.
Key Insights The considerable ownership by individual investors in Omeros indicates that they collectively have a...